Cell Research, 8 March, 2022, DOI：https://doi.org/10.1038/s41422-022-00634-w
Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine
Hua Peng & Yang-Xin Fu
New adjuvants that potently improve vaccine efficacy with extremely low toxicity are urgently needed. In a recent study in Cell Research, Liu et al. show that a new STING agonist CF501 facilitates a SARS-CoV-2 subunit vaccine to elicit robust neutralizing antibody response against several subtypes of sarbecovirus and protects experimental animals from SARS-CoV-2 infection.